Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.

Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS.

Haematologica. 2014 Aug;99(8):1373-9. doi: 10.3324/haematol.2014.103655. Epub 2014 May 9.

2.

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).

Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA; Alliance for Clinical Trials in Oncology.

Invest New Drugs. 2013 Oct;31(5):1311-20. doi: 10.1007/s10637-013-9978-z. Epub 2013 May 23.

3.

Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.

O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K.

Leuk Lymphoma. 2010 Dec;51(12):2240-9. doi: 10.3109/10428194.2010.520773. Epub 2010 Oct 4.

4.

DNA repair genes, electromagnetic fields and susceptibility to acute leukemia?

Sharma M, Odenike OM.

Leuk Lymphoma. 2008 Dec;49(12):2233-4. doi: 10.1080/10428190802573123. No abstract available.

PMID:
19052967
5.

Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.

Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, Stock W.

Clin Cancer Res. 2008 Nov 1;14(21):7095-101. doi: 10.1158/1078-0432.CCR-08-1007.

6.

Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.

Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA.

Leuk Lymphoma. 2008 Jul;49(7):1274-8. doi: 10.1080/10428190802043887.

7.

Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock W.

Invest New Drugs. 2008 Jun;26(3):233-9. doi: 10.1007/s10637-008-9115-6. Epub 2008 Jan 24.

8.

Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.

Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K.

Bone Marrow Transplant. 2007 Dec;40(11):1027-32. Epub 2007 Sep 10.

PMID:
17846595
9.

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, Larson RA; Cancer and Leukemia Group B.

Clin Cancer Res. 2005 Jun 1;11(11):4176-81.

10.

Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.

Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF.

J Clin Oncol. 2004 Dec 1;22(23):4816-22. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570084
11.

A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.

Odenike OM, Sobecks RM, Janisch L, Huo D, Zimmerman TM, Daugherty CK, Ratain MJ, Larson RA.

Cancer Chemother Pharmacol. 2004 Dec;54(6):553-61. Epub 2004 Sep 2.

PMID:
15349753

Supplemental Content

Loading ...
Support Center